3 period full repli­cate [RSABE / ABEL]

posted by Dr_Dan  – Germany, 2015-06-24 15:55 (3219 d 12:36 ago) – Posting: # 14974
Views: 31,481

Dear all
From a leading European regulatory authority I just recieved the information that a 3-period full replicate design (two sequences: T-R-T and R-T-R) for a bioequivalence study will not be accepted. The reason is that

for a full replicate design R as well as T need to be replicated and this is only possible with the res­pec­tive sequences (so TTRR etc.). A 3-period full replicate design would result only in two parallel sepa­rate groups (one which – apart from the integrated 2-period crossover– only get Test and the other only Reference); an evaluation would probably only possible as a general 2-period crossover study.

Please excuse the confusing explanation but the text set in italic is the verbal translation from what I received.
My interest is just of academic nature: What should one reply to this attitude?
Looking forward to your replies and to a fruitful discussion.
Kind regards
Dr_Dan


Edit: Category changed from Design Issues. I think this category fits better – especially if one is inter­ested in reference-scaling. [Helmut]

Kind regards and have a nice day
Dr_Dan

Complete thread:

UA Flag
Activity
 Admin contact
22,984 posts in 4,822 threads, 1,654 registered users;
51 visitors (0 registered, 51 guests [including 8 identified bots]).
Forum time: 04:31 CEST (Europe/Vienna)

Complex, statistically improbable things are by their nature
more difficult to explain than
simple, statistically probable things.    Richard Dawkins

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5